The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Efficacy and safety of pramipexole in restless legs syndrome
Abstract
OBJECTIVE: To evaluate the efficacy and safety of pramipexole in patients with moderate to severe restless legs syndrome (RLS) METHODS: The authors conducted a 12-week, double-blind, randomized, placebo-controlled trial of fixed doses of pramipexole (0.25, 0.50, and 0.75 mg/day). Patients (N = 344) were up-titrated to their randomized dose over 3 weeks. The primary efficacy endpoints were patient ratings of symptom severity on the International RLS Study Group Rating Scale (IRLS) and clinician ratings of improvement on the Clinical Global Impressions-Improvement (CGI-I) scale. Secondary efficacy endpoints included visual analogue ratings of sleep and quality of life (QOL) RESULTS: By both primary measures, pramipexole was superior to placebo. For IRLS, the adjusted mean (SE) change from baseline to week 12 was -9.3 (1.0) for placebo, -12.8 (1.0) for 0.25 mg/day, -13.8 (1.0) for 0.50 mg/day, and -14.0 (1.0) for 0.75 mg/day (all p < 0.01). Similarly, pramipexole increased the percentage of patients with a CGI-I rating of "very much improved" or "much improved" at the end of the trial (51.2% for placebo and 74.7%, 67.9%, and 72.9% for pramipexole; all p < 0.05). Pramipexole significantly improved ratings of symptom severity, day and night, and also ratings of sleep satisfaction and QOL. Pramipexole was well tolerated: The most frequent adverse events with higher occurrence in the pramipexole group were nausea (19.0% vs 4.7%) and somnolence (10.1% vs 4.7%) CONCLUSION: As rated by patients and by clinicians, pramipexole was efficacious and safe in reducing the symptoms of restless legs syndrome.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Method for Measuring Daytime Sleepiness: The Epworth Sleepiness Scale
Johns, M. W. (1991) · Sleep · doi:10.1093/sleep/14.6.540 · Cited by 17,364
Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology
Allen, R. P., Picchietti, D., Hening, W. A., Trenkwalder, C., Walters, A. S., & Montplaisi, J. (2003) · Sleep Medicine · doi:10.1016/s1389-9457(03)00010-8 · Cited by 2,900
Placebo Response in Studies of Major Depression: Variable, Substantial, and Growing
Walsh, B. T., Seidman, S. N., Sysko, R., & Gould, M. (2002) · JAMA · doi:10.1001/jama.287.14.1840 · Cited by 1,109
Cited by
Allen, R. P., Picchietti, D. L., Garcia-Borreguero, D., Ondo, W. G., Walters, A. S., Winkelman, J. W., Zucconi, M., Ferri, R., Trenkwalder, C., & Lee, H. B. (2014) · Sleep Medicine · doi:10.1016/j.sleep.2014.03.025 · Cited by 1,609
Self-citationThe scientific and clinical basis for the treatment of Parkinson disease (2009)
Olanow, C. W., Stern, M. B., & Sethi, K. (2009) · Neurology · doi:10.1212/wnl.0b013e3181a1d44c · Cited by 908
Self-citationWalters, A. S., & Rye, D. B. (2009) · Sleep · doi:10.1093/sleep/32.5.589 · Cited by 425
Restless legs syndrome: pathophysiology, clinical presentation and management
Trenkwalder, C., & Paulus, W. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.55 · Cited by 310
Aurora, R. N., Kristo, D. A., Bista, S. R., Rowley, J. A., Zak, R. S., Casey, K. R., Lamm, C. I., Tracy, S. L., & Rosenberg, R. S. (2012) · SLEEP · doi:10.5665/sleep.1988 · Cited by 303
Metadata
- Authors
- Winkelman, J. W., Sethi, K. D., Kushida, C. A., Becker, P. M., Koester, J., Cappola, J. J., & Reess, J.
- Venue
- Neurology
- Published
- 2006-09-26
- Volume
- 67
- Issue
- 6
- Pages
- 1034-1039
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2034430472
- Cited by
- 196
- References
- 3
- FWCI
- 16.82
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of pramipexole in restless legs syndrome. https://app.cochat.ai/papers/10.1212/01.wnl.0000231513.23919.a1
- The paper
- Winkelman, J. W., Sethi, K. D., Kushida, C. A., Becker, P. M., Koester, J., Cappola, J. J., & Reess, J. (2006). Efficacy and safety of pramipexole in restless legs syndrome. Neurology. https://doi.org/10.1212/01.wnl.0000231513.23919.a1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.